Specialty Pharmacy

Research may improve the design of pharmaceuticals for leukemia and other types of cancer.

Many RA treatments suppress the immune system, leaving patients at risk for contracting a potentially fatal infection.

Breast Cancer and the Environment Research Program will focus on racially and ethnically diverse communities and expand the study of risk factors.

Panel discusses treatment barriers during annual NASP conference.

Factor X deficiency prevents blood from clotting properly.

Atheer Kaddis, PharmD, senior vice president of Business Development and Sales at Diplomat, discusses services offered by Diplomat's Hospital Specialty Program.

Despite new advanced immunotherapies, surgical resection still is the most effective treatment for abdominal metastatic melanoma.

Pfizer asked to provide additional safety analyses for proposed indication.

Existing medications and myxoma virus combination shows promise against glioblastoma.

Medicare Part D is nearly 50% under budget with premiums almost 40% less than originally projected.

Process responsible for cancer cell proliferation uncovered.

A little more than a year has passed since the Drug Enforcement Administration (DEA) announced that pharmacies could collect and destroy unused prescription drugs, but what kind of impact has this regulation made?

HDAC inhibitors stop the activation of genes that turn normal cells into cancerous cells.

Researchers raise concerns that studies reporting negative results are not published, leading to overestimated drug efficacy.

Gel may eventually eliminate the need for animal testing in medical research.

A new study found financial integration between physicians and hospitals has led to higher spending in outpatient care.

Test may help clinicians identify the best course of therapy for patients with Diffuse Large B-Cell Lymphoma.

Immune mechanisms found to have significant impact on overcoming HCV.

Researchers seek to increase transparency and diminish the added burdens on the workforce.

Pan-virals show potential to work across all HCV genotypes.

DNA4Life has launched a new test for patients who want to know how their bodies will respond to some of the most commonly prescribed therapeutic medications.

Multiple myeloma disease development affected by pituitary tumor transforming gene.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.

Research may improve the diagnosis of infectious and autoimmune diseases, including rheumatoid arthritis and HIV.

Research may minimize operations for benign disease while maintaining a low morbidity and mortality for surgical resection.

Researchers seek to improve diagnosis, support genetic counseling, and enhance medical management.

Treatment doubles overall survival of patients with recurrent glioblastoma.

Injection drug use most frequently linked to a positive hepatitis C screening.

Process makes tumors more sensitive to chemotherapy to improve targeted therapy.

Top news of the week in cancer drug development.